';

Neovasc Tiara™ TMVR results presented at CRT 2019 meeting in Washington

March 4, 2019

VANCOUVER, March 4, 2019 – Neovasc Inc. (“Neovasc” or the “Company”), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that its Tiara™ (“Tiara”) transcatheter mitral valve replacement device was featured in an update presentation at the Cardiovascular Research Technologies (CRT) meeting being held March 2-5, 2019 in Washington, DC.

The update presentation was provided by Danny Dvir, MD, of the Cardiac Clinic & Services at the University of Washington Medical Center, and titled, “TIARA: Design, Clinical Results and Next Steps” on Sunday, March 3rd.  The presentation provided an overview of the data from the 70 patients that have been treated to date with the Tiara mitral valve replacement device, including 25 patients in the TIARA-II European CE Mark Clinical Study, 23 patients in TIARA-I Early Feasibility Clinical Study and 22 patients in Special Access/Compassionate Use. This presentation also included data on the successful use of Tiara in patients with previous aortic valve replacements and mitral rings. Similar data was recently published in Circulation: Cardiovascular Interventions, on “Transcatheter Mitral Valve Replacement in Patients with Previous Aortic Valve replacement”. The University of Washington Medical Center is a participating center in the TIARA-I Early Feasibility Study.

CRT, one of the world’s leading interventional cardiology conferences, is attended by more than 3,000 interventional and endovascular specialists. The conference, held each year in Washington, DC, is supported by MedStar Heart & Vascular Institute and serves as a forum for physician and health-care professional education about new cardiovascular technology and interventional procedures in the field. The meeting is actually several conferences at once, with tracks including CRT Valve & Structural, CRT Endovascular.